40
CME Program for Family CME Program for Family Physicians Physicians Ambulatory BP Ambulatory BP Monitoring Monitoring Brian Gore, MD CCFP Dip Brian Gore, MD CCFP Dip Epid. Epid. Part II Part II ABPM ABPM

Evolving to newer technologies …

Embed Size (px)

DESCRIPTION

CME Program for Family Physicians Ambulatory BP Monitoring Brian Gore, MD CCFP Dip Epid. Part II ABPM. Evolving to newer technologies …. Clinical Indications for ABPM. Clinical Indications for ABPM T Pickering, Am J Hyperten, 1996, O’Brien, Prague ISH, June 2002. - PowerPoint PPT Presentation

Citation preview

Page 1: Evolving to newer technologies …

CME Program for Family CME Program for Family

PhysiciansPhysicians Ambulatory BP Ambulatory BP

MonitoringMonitoring

Brian Gore, MD CCFP Dip Epid.Brian Gore, MD CCFP Dip Epid.

Part IIPart IIABPMABPM

Page 2: Evolving to newer technologies …

Evolving to newer technologiesEvolving to newer technologies….….

Page 3: Evolving to newer technologies …
Page 4: Evolving to newer technologies …

Clinical Indications for Clinical Indications for ABPMABPM

Page 5: Evolving to newer technologies …

Clinical Indications for ABPMClinical Indications for ABPMT Pickering, Am J Hyperten, 1996, O’Brien, Prague ISH, June 2002T Pickering, Am J Hyperten, 1996, O’Brien, Prague ISH, June 2002

Suspected WCH or WCE w/o target Suspected WCH or WCE w/o target organ damageorgan damage

Evaluation of treatment resistant HTNEvaluation of treatment resistant HTN Hypotension symptoms on Hypotension symptoms on

antihypertensive medicationantihypertensive medication

Page 6: Evolving to newer technologies …

Clinical Indications Clinical Indications (cont)(cont)T Pickering, Am J Hyperten, 1996, O’Brien, Prague ISH, June 2002T Pickering, Am J Hyperten, 1996, O’Brien, Prague ISH, June 2002

Intermittent symptoms possibly related Intermittent symptoms possibly related to blood pressure (postural, to blood pressure (postural, postprandial)postprandial)

Nocturnal hypertension (sleep apnea, Nocturnal hypertension (sleep apnea, diabetics)diabetics)

Autonomic failure: diabeticsAutonomic failure: diabetics

Page 7: Evolving to newer technologies …

What to assess in an ABPMWhat to assess in an ABPM EvaluationEvaluation

ABPM readings: quality, #, pattern. ABPM readings: quality, #, pattern. Periods: total 24 hour, awake, asleep.Periods: total 24 hour, awake, asleep. Dipper status: Y,N, Excessive, ReverseDipper status: Y,N, Excessive, Reverse 24-hour pulse pressure.24-hour pulse pressure. White coat HTN or effect.White coat HTN or effect. Heart rate and rate-pressure productHeart rate and rate-pressure product..

Page 8: Evolving to newer technologies …

Summary Guide to Interpret ABPM Analyzing the data:Analyzing the data:

Minimum number acceptable:

14 readings day-time

7 readings night-time 

O’Brien, BMJ: 2001

Page 9: Evolving to newer technologies …

Summary Guide to Interpret ABPM Results Summary Guide to Interpret ABPM Results

Analyzing the data 1:Analyzing the data 1:  

 

ABPM profiles:       

- - normal day and night periods     - white coat syndrome (includes WCH + WCE)     - borderline hypertension      - nocturnal hypertension       

Page 10: Evolving to newer technologies …

Summary Guide to Interpret ABPM Results Summary Guide to Interpret ABPM Results

Analyzing the data 2:Analyzing the data 2:

ABPM profiles:       

 - systolic and diastolic hypertension + dipper     - systolic and diastolic hypertension + non-dipper - isolated systolic hypertension       - isolated diastolic hypertension      - excessive BP variability

Page 11: Evolving to newer technologies …

What are normal ABPM limitsWhat are normal ABPM limits

Are office BP readings comparable Are office BP readings comparable

to ABPM values ?to ABPM values ?

Page 12: Evolving to newer technologies …

Recommended standards for normal and abnormal pressures during ABPM.

These pressures are only a guide, and lower pressures may be abnormal in patients whose total risk factor profile is high and in whom there is concomitant disease.

Normal Abnormal

Day    135/85 >140/90

Night    120/70 >125/75

24 hour    130/80 >135/85

Page 13: Evolving to newer technologies …

O p era tio n a l A p p ro a ch fo r C V R isk S ra tif ica tio nV e rd e c c h ia , V . J H yp e rte ns io n 2 0 0 0 ; 3 5 :8 4 4 -8 5 1

LO W R I SK

Day- tim e ABP < 135/ 85O ptim al < 130/ 80

W hite Coat Hypertension

INTERMEDIATE RISK

Dipper (> 10% )N orm al 24 h PP

< 53 m m H g

HIGH RISK

N ondipperSBP Day to n ight reduction < 10%

HIGH RISK

I ncreased 24 hr PP> 53 m m H g

Am bulatory Hypertension

Untreated OHT

Page 14: Evolving to newer technologies …

ABPM PatternsABPM Patterns

O’Brien, BMJ, April, 2000O’Brien, BMJ, April, 2000

B. Gore, personal database, 2003B. Gore, personal database, 2003

Page 15: Evolving to newer technologies …

Normal 24 hour ABPMNormal 24 hour ABPM

Page 16: Evolving to newer technologies …

White Coat HypertensionWhite Coat Hypertension

Page 17: Evolving to newer technologies …

White coat hypertensionWhite coat hypertension

Page 18: Evolving to newer technologies …

Prevalence of White Coat Prevalence of White Coat HypertensionHypertension

Ranges from 10-30% of hypertensive Ranges from 10-30% of hypertensive population based on review of population based on review of

clinical trialsclinical trials

Page 19: Evolving to newer technologies …

Implications of WCEImplications of WCE

Overestimation of OBP Overestimation of OBP Potential for overtreatmentPotential for overtreatment Nonresponse to RxNonresponse to Rx Potential Rx adverse Potential Rx adverse

effectseffects

Page 20: Evolving to newer technologies …

Stage 1 hypertensive dipperStage 1 hypertensive dipper

Page 21: Evolving to newer technologies …

Stage 2 hypertensive dipperStage 2 hypertensive dipper

Page 22: Evolving to newer technologies …

Hypertensive Dipper (>SHTN)Hypertensive Dipper (>SHTN)

Page 23: Evolving to newer technologies …

Isolated Systolic HTNIsolated Systolic HTN

Page 24: Evolving to newer technologies …

Hypertensive Non-DipperHypertensive Non-Dipper

Page 25: Evolving to newer technologies …

Stage 3 HTN Non-DipperStage 3 HTN Non-Dipper

Page 26: Evolving to newer technologies …

Dippers and Non-DippersDippers and Non-Dippers

Dipper:Dipper: Day/Night >10/5 Day/Night >10/5 mmHgmmHg

Non-Dipper: Day/Night <10/5 mmHgNon-Dipper: Day/Night <10/5 mmHg

Dipper: Stroke 3%Dipper: Stroke 3% Non-Dipper: Stroke 23%Non-Dipper: Stroke 23%

O’Brien et al, Lancet 1988O’Brien et al, Lancet 1988

Page 27: Evolving to newer technologies …

ABPM IntrigueABPM Intrigue

Page 28: Evolving to newer technologies …

Normal 24 hr ABP with morning surgeNormal 24 hr ABP with morning surge

Page 29: Evolving to newer technologies …

CV Events that are Coincident with CV Events that are Coincident with Morning Blood Pressure ‘Surge’Morning Blood Pressure ‘Surge’

Myocardial ischemiaMyocardial ischemia

Myocardial infarctionMyocardial infarction

Sudden cardiac deathSudden cardiac death

StrokeStroke

ThromboticThrombotic HemorrhagicHemorrhagic

Adapted from: Muller, et al. 1985; Rocco, et al. 1987; Marler, et al. 1989; Willich, et al. 1992.

Page 30: Evolving to newer technologies …

Case: Case: Gertrude H is a 77 year-old Gertrude H is a 77 year-old femalefemale

Past History:Past History:

Diabetes type 2 for 5 years, Diabetes type 2 for 5 years, HTN, hyperlipidemia.HTN, hyperlipidemia.

OBP: 160/102OBP: 160/102

FU OBP: 166/98 (2 weeks)FU OBP: 166/98 (2 weeks)

Physical exam: Physical exam: Unremarkable. Unremarkable.

BMI: 30.BMI: 30.

Meds: Ramipril 10, HCTZ Meds: Ramipril 10, HCTZ 12.5 mg, Metformin 500 tid, 12.5 mg, Metformin 500 tid, Lipitor 20 qhs.Lipitor 20 qhs.

Significant lab:Significant lab:

CV Risk Ratio: 5.62CV Risk Ratio: 5.62

MAU 0.06 mcg/mlMAU 0.06 mcg/ml

HbA1c: .085HbA1c: .085

24-hr ABPM results:24-hr ABPM results:

24 hour abnormal ABP with 24 hour abnormal ABP with marked nocturnal marked nocturnal hypertension: commonly hypertension: commonly found in patients with found in patients with diabetes and loss of diabetes and loss of glycemic control or in glycemic control or in patients with sleep apnea.patients with sleep apnea.

Page 31: Evolving to newer technologies …

S+D HTN with Nocturnal HypertensionS+D HTN with Nocturnal Hypertension

Page 32: Evolving to newer technologies …

Inherent Variability of BP

Page 33: Evolving to newer technologies …

Blood Pressure Variability and Target Organ Damage: A Longitudinal Analysis

Adapted from: Frattola, et al. 1993.

p<0.01150

120

140

130

110

100

90

LVMI (g/m2)

< 95 95–108 109–120 >120

Initial 24-hour MAP (mm Hg)

n=73

Variability <group average

Variability >group average

10 8 11 8 11 9 8 8

Page 34: Evolving to newer technologies …

OvertreatmentOvertreatment

Page 35: Evolving to newer technologies …

Autonomic Dysregulation:Autonomic Dysregulation:

Typical patient characteristics:Typical patient characteristics:

65 year old female with:65 year old female with:

TOD/CCVD: CAD, LVH, CABG, TOD/CCVD: CAD, LVH, CABG, CVA, Remote MI.CVA, Remote MI.

CO-MORBIDITY: DIABETES. CO-MORBIDITY: DIABETES.

CV-RF: AGE, PM, SMOKER, CV-RF: AGE, PM, SMOKER, HYPERLIPIDEMIAHYPERLIPIDEMIA

OBPOBP: : 170-180/90170-180/90

Physical examPhysical exam: Carotid bruits, : Carotid bruits, Reduced PP’s, trophic leg changes, Reduced PP’s, trophic leg changes, Mild weakness RA. Mild weakness RA.

BMI: 29.BMI: 29.

MedsMeds: : Metroprolol 100 mg bid, Metroprolol 100 mg bid, Cozaar 100 mg qam,Cozaar 100 mg qam, Metformin Metformin 500 tid, Lipitor 20 qhs, ASA 80 mg 500 tid, Lipitor 20 qhs, ASA 80 mg QD.QD.

Lab Investigations:Lab Investigations:

TC-6.52, HDL-1.05, LDL-5.1TC-6.52, HDL-1.05, LDL-5.1

TG: 3.2, CV Risk Ratio:TG: 3.2, CV Risk Ratio:6.216.21

Proteinuria >3gm/l. HgB A1C: Proteinuria >3gm/l. HgB A1C: 0.078.0.078.

EKG: LVH, Remote inferior MI.EKG: LVH, Remote inferior MI.

Referred to evaluate 24 hour Referred to evaluate 24 hour control in view of persistently control in view of persistently high OBPhigh OBP

The Dilemma: BP management in The Dilemma: BP management in light of ABPM resultslight of ABPM results..

Page 36: Evolving to newer technologies …

Autonomic DysfunctionAutonomic Dysfunction

Page 37: Evolving to newer technologies …

Other ABP Illustrations:Other ABP Illustrations:“Trouble Coming”“Trouble Coming”

Page 38: Evolving to newer technologies …

Stroke Range HypertensionStroke Range Hypertension

Page 39: Evolving to newer technologies …

Isolated SHTN and high risk 24-hr pulse Isolated SHTN and high risk 24-hr pulse pressurepressure

Page 40: Evolving to newer technologies …

Total period: 20 hour 44 min 4/3/2003 10:26 - 4/4/2003 10:26 (51 data)

 

SBP DBP MAP PP HR Double prod.

Mean 162 68 99 94 mmHg 56 /min 9165 Max 214 95 135 127 mmHg 67 /min 13054 Min 132 55 82 73 mmHg 46 /min 6480

SD 20 9 12 14 mmHg 6 /min 1838 DI 13 11 12 % PTE 98 8 66 % Load 781 5 127 mmHg*h/24h